Pathologic variants of the mitochondrial phosphate carrier SLC25A3: Two new patients and expansion of the cardiomyopathy/skeletal myopathy phenotype with and without lactic acidosis

Document Type

Journal Article

Publication Date

1-1-2015

Journal

JIMD Reports

Volume

19

DOI

10.1007/8904_2014_364

Keywords

Alpha galactosidase; Hypertrophic cardiomyopathy; Lactic acidosis; Patent ductus arteriosus; Skeletal myopathy

Abstract

Variants in the SLC25A3 gene, which codes for the mitochondrial phosphate transporter (PiC), lead to a failure of inorganic phosphate (Pi) transport across the mitochondrial membrane, which is required in the final step of oxidative phosphorylation. The literature described two affected sibships with variants in SLC25A3; all cases had skeletal myopathy and cardiomyopathy (OMIM 610773). We report here two new patients who had neonatal cardiomyopathy; one of whom did not have skeletal myopathy nor elevated lactate. Patient 1 had a homozygous splice site variant, c.158-9A>G, which has been previously reported in a Turkish family. Patient 2 was found to be a compound heterozygote for two novel variants, c.599T>G (p.Leu200Trp) and c. 886_898delGGTAGCAGTGCTTinsCAGATAC (p.Gly296_Ser300delinsGlnIlePro). Protein structure analysis indicated that both variants are likely to be pathogenic. Sequencing of SLC25A3 should be considered in patients with isolated cardiomyopathy, even those without generalized skeletal myopathy or lactic acidosis.

This document is currently not available here.

Share

COinS